🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shenzhen 43
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shenzhen Geno-Immune Medical Institute43 Beijing Biotech32 Sun Yat-sen University23 Bristol-Myers Squibb19 Shenzhen University General Hospital11 Clear sponsor filter
Site location
Shenzhen43
All 1 locations
Target enrolment
to

Trials with a site in Shenzhen

43 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Combination Immunotherapy Targeting Sarcomas
NCT04433221Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2027-07-01
Not yet open
Lentiviral Gene Therapy for CGD
NCT03645486Chronic Granulomatous Disease
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-07-01
Not yet open
CAR-T Immunotherapy Targeting CD19- ALL
NCT04016129B-cell Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-07-01
Not yet open
Universal CAR-T Cells Targeting AML
NCT05995041Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2027-06-30
Not yet open
Engineered Dendritic Cell Vaccines for Multiple Myeloma
NCT06435910Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2027-06-30
Not yet open
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
NCT06435897Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)
NCT03645460Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-06-30
Not yet open
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
NCT03217617SCID, X-Linked
Shenzhen Geno-Immune Medical Institute
Phase 1/2
10
Shenzhen
2027-06-30
Not yet open
Combination Immunotherapy Targeting Melanoma
NCT06739226Melanoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
cfMSC Stem Cell Therapy Targeting COPD
NCT07477600Chronic Obstructive Pulmonary Disease (COPD)
DrugClonal fetal MSCs
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
Universal 4SCAR7U Targeting CD7-positive Malignancies
NCT05995028T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2027-06-30
Not yet open
cfMSC Therapy for Diabetes
NCT07495956Type II Diabetes Mellitus
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
Universal CAR-T Cells Targeting Multiple Myeloma
NCT06006741Multiple Myeloma in Remission
Shenzhen Geno-Immune Medical Institute
Phase 1
20
Shenzhen
2027-06-30
Not yet open
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
NCT07501156Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
IT and IV Lentiviral Gene Therapy for X-ALD
NCT03727555X-linked Adrenoleukodystrophy
Shenzhen Geno-Immune Medical Institute
Not applicable
30
Shenzhen
2027-06-01
Not yet open
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
NCT07046338Metachromatic Leukodystrophy (MLD)
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-06-01
Not yet open
CD19/70 Bi-specific CAR-T Cell Therapy
NCT05436496B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-01
Not yet open
DLL3 CAR-T Therapy Targeting Brain Tumors
NCT07180927Glioblastoma of Cerebellum
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-01
Not yet open
Multi-4SCAR-T Therapy Targeting Breast Cancer
NCT04430595Breast Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-06-01
Not yet open
Multi-CAR-T Cells Targeting B Cell Lymphomas
NCT04429438B Cell Lymphoma (BCL)
Shenzhen Geno-Immune Medical Institute
Phase 1/2
11
Shenzhen
2027-06-01
Not yet open
Lentiviral FIX Gene Therapy
NCT03961243Hemophilia B
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2027-06-01
Not yet open
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
NCT04432649Solid Tumor
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-06-01
Not yet open
Lentiviral FVIII Gene Therapy
NCT03217032Hemophilia A
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2027-06-01
Not yet open
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
NCT03356782Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2027-06-01
Not yet open
CAR-T Cells Targeting Autoimmune Diseases
NCT05459870Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-01
Not yet open
CD19/22 Bi-specific CAR-T Cell Therapy
NCT05432882B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2
60
Shenzhen
2027-06-01
Not yet open
Immunotherapy Treating GI Cancer
NCT03614650Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-06-01
Not yet open
Antigen-specific T Cells Against Lung Cancer
NCT03356808Lung Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2027-06-01
Not yet open
Direct Lentiviral Injection Gene Therapy for MLD
NCT03725670Metachromatic Leukodystrophy (MLD)
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-05-31
Not yet open
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
NCT06429150Multiple Myeloma, Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2026-12-31
Not yet open
4SCAR19U T Cells Targeting B Cell Malignancies
NCT05995015B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2026-12-31
Not yet open
GD2/PSMA Bi-specific CAR-T Cell Therapy
NCT05437315Solid Tumor
Shenzhen Geno-Immune Medical Institute
Phase 1/2
60
Shenzhen
2026-12-31
Not yet open
PSMA-specific CAR-T Cell Therapy
NCT04429451PSMA Positive Tumors or Tumor Tissues
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
NCT04033302T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2026-12-31
Not yet open
Immune Modulatory DC Vaccine Against Brain Tumor
NCT03914768Diffuse Intrinsic Pontine Glioma or Glioblastoma
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2026-12-31
Not yet open
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
NCT03351829Beta-Thalassemia
Shenzhen Geno-Immune Medical Institute
Not applicable
20
Shenzhen
2026-12-31
Not yet open
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
NCT02992210Solid Tumor
Shenzhen Geno-Immune Medical Institute
Phase 1/2
10
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
NCT03271632Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
NCT03222674Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1/2
10
Shenzhen
2026-12-31
Not yet open
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
NCT04637503Neuroblastoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2026-12-31
Not yet open
GD2/CD70 Bi-specific CAR-T Cell Therapy
NCT05438368Cancer Disease
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2026-12-31
Not yet open
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders
NCT03123458Immune Related Disorder, Tissue Damage
DrugClonal fetal MSCs
Shenzhen Geno-Immune Medical Institute
Phase 1
100
Shenzhen
2026-12-31
By invitation
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
NCT03393962Ovarian Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2025-12-01
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Shenzhen that also match the filters currently applied.

How many clinical trials are recruiting in Shenzhen?

0 of the 43 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 42 have not yet opened recruitment, 0 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shenzhen), 43 studies
PhaseStudiesRecruitingShare
Phase 1/228065.1%
Phase 19020.9%
Not applicable6014%

Most active sponsors

Lead sponsors with the most studies (Shenzhen)
Lead sponsorStudiesRecruiting
Shenzhen Geno-Immune Medical Institute430
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.